Arrivent Biopharma, Inc.

This early-stage study is testing an experimental drug called furmonertinib for people with advanced lung cancer that has specific genetic mutations. The trial aims to find the safest and most effective dose while checking if the drug can shrink tumors. It involves 160 patients w…